HOME >> BIOLOGY >> NEWS
First glimpse of DNA binding to viral enzyme

UPTON, NY -- Scientists at the U.S. Department of Energy's Brookhaven National Laboratory and the Albert Einstein College of Medicine have produced the first molecular-scale images of DNA binding to an adenovirus enzyme -- a step they believe is essential for the virus to cause infection. The images, which appear on the cover of the October 2004 issue of Molecular and Cellular Proteomics, show how binding to DNA may stimulate the enzyme and are already being used to design new antiviral drugs to block this interaction.

"We were quite surprised to see that DNA actually stimulated the activity of the enzyme," said Brookhaven biologist Walter Mangel, a co-author on the paper. "If we can block this interaction, we should be able to prevent the virus from replicating, and thereby thwart infection."

Adenoviruses cause respiratory, gastrointestinal, and eye infections, including highly contagious viral pink eye. Some adenovirus eye infections lead to blindness. Respiratory epidemics of adenovirus are often prevalent on army bases. And in patients with compromised immune systems, such as those infected with human immunodeficiency virus (HIV), an opportunistic adenovirus infection can be deadly.

During infection, adenovirus makes an enzyme called a protease, which cleaves or degrades viral "scaffolding" proteins to complete the maturation of newly synthesized virus particles. Mangel and others have been working to understand all the steps necessary for this enzyme's function, looking for new ways to stop its action and, therefore, block an adenovirus infection (see: http://www.bnl.gov/discover/Spring_04/anti_viral_1.asp).

The scientists didn't expect the viral DNA to bind to the protease, but they figured they should look just to rule out such an interaction. "It was something we had to do, to make sure they did not interact," Mangel said. The discovery that the v
'"/>

Contact: Karen McNulty Walsh
kmcnulty@bnl.gov
631-344-8350
DOE/Brookhaven National Laboratory
13-Sep-2004


Page: 1 2 3

Related biology news :

1. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults
2. 2nd media alert First Scientific Conference on Childhood Leukaemia
3. First International Scientific Conference on Childhood Leukaemia
4. First ever standards linking climate change, biodiversity and poverty seek global peer review
5. First genetic comparison of purebred domestic dogs produces surprises
6. First time in the U.S.: Saint Louis University tests third-generation vaccine against smallpox
7. First target for childhood malaria vaccine
8. First study of resveratrol dietary supplement finds effect on breast and prostate cancers unlikely
9. First flavors form a lasting impression
10. STN International launches Derwent World Patents Index First View
11. First DFG research conference in the USA

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/23/2019)... ... March 22, 2019 , ... ... Next Generation Sequencing (NGS) sample preparation. RhinoSeq employs a proprietary kit chemistry that ... five-tube kit is comprised of preformatted master mixes for a simple, fast, and ...
(Date:3/18/2019)... FRANCISCO (PRWEB) , ... March 18, 2019 , ... ... patent portfolio in the microbiome industry and the third highest quality portfolio following ... by authors Manuel Fankhauser, Christian Moser, and Theodor Myfleler. uBiome executives Dr. ...
(Date:3/14/2019)... INDIANAPOLIS (PRWEB) , ... March 14, 2019 , ... ... and configurations on Mac, Windows and mobile, today announces the launch of its ... on sales volume, geographies and vertical markets, enabling them to add FileWave’s industry-leading ...
Breaking Biology News(10 mins):
(Date:3/14/2019)... OKLAHOMA CITY (PRWEB) , ... March 14, 2019 ... ... AAALAC International for their facility in Oklahoma City, OK. EyeCRO joins the Department ... University of Oklahoma Health Sciences Center as the fifth institution in Oklahoma to ...
(Date:3/14/2019)... ... March 14, 2019 , ... ON NOVEMBER 27, 2018, Nova ... Eye Machine Canada Inc., had been given approval to begin a clinical patient ... Degeneration (AMD). , The previous month, the medical devices bureau of Health Canada ...
(Date:3/14/2019)... LAWRENCEVILLE, N.J. (PRWEB) , ... ... ... announced the launch of a preclinical gold standard solution for preclinical research ... Execution System (LES) with end-to-end workflows, connected systems and facilities, innovative technology-driven ...
(Date:3/11/2019)... ... March 11, 2019 , ... In this live webinar, the ... your clinical trial efficiency and experience. Participants will learn how to use the information ... to ensure that the simple or complex randomization scheme is properly designed and set ...
Breaking Biology Technology:
Cached News: